STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Illumina, a United States-headquartered company specializing in DNA sequencing and array-based technologies, is showcasing ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

Johnson & Johnson is a global leader in the pharmaceutical, medical device and consumer ... which closed at $54.92 on Oct. 14. Gilead Sciences is a biopharmaceutical company that develops ...

Gilead Sciences (GILD) has been one of the most searched ... During this period, the Zacks Medical - Biomedical and Genetics industry, which Gilead falls in, has lost 1.9%. The key question ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leading pharmaceutical and health-care companies have gained confidence from the positive results from previous editions of ...

About Gilead Sciences, Inc. Gilead Sciences ... Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.